Expert consensus recommends managing hyperkalaemia to maintain life-saving RAASi therapy in cardiovascular patients rather than discontinuing the medication.
No takes yet. Share an insight, caveat, or question.
Endorses RAASi as foundational across HF, hypertension, diabetes, and CKD; reinforces guideline-directed use with proven endpoint benefits.
Rosano et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: